Evaluation of biochemical and economic outcomes in patients treated with PCSK9 inhibitors in a real clinical practice setting
BACKGRO UND : PCSK9 inhibitors (PCSK9i) in combination with high-dose statins can reduce LDL -cholesterol (LDL-C) levels by 50-60% over statin monotherapy. This analysis investigated biochemical (LDL-C reduction) and economic outcomes in Italian patients treated with PCSK9i or potentially eligible but untreated.METHOD S: Administrative databases of healthcare institutions covering around 5 million residents were used… Read More »Evaluation of biochemical and economic outcomes in patients treated with PCSK9 inhibitors in a real clinical practice setting
The Integrated Multidisciplinary Pathway for Large-Scale Management of Dyslipidemia in High-Risk Patients (ENNA) Project: Rationale and Project Design
Atherosclerotic cardiovasculardiseaseisaleadingcauseofmorbidityandmortalityglobally,significantlyinfluenced bymodifiable riskfactors,particularlyhypercholesterolemia.Despitetheavailabilityofeffectivelipid-reducing drugs,achievingthelow-densitylipoproteincholesterol(LDL-C)targetlevelsremainsasignif-icant challengeinclinicalpractice,contributingtopersistentlyhighratesofcardiovascularevents.TheintE-grated multidiscipliNarypathwayforlarge-scalemaNagementofdyslipidemiAinhigh-riskpatients(ENNA)Project wasdesignedtoaddressthealarmingratesofsuboptimallipidmanagementinpatientsathighandvery-high riskintheprovinceofEnna,Sicily.ThisprogramaimstooptimizeLDL-Ccontrolthroughaninte-grated caremodelthatfosterscollaborationamongpharmacists,generalpractitioners,andcardiologists,ulti-mately promotingapatient-centeredapproachtotherapy.Thepatientswhoareeligibleareidentified usingdata-driven methodsthroughprescriptionclaims,laboratoryresults,andhospitaldischargedata,facilitatedby localpharmacies.Generalpractitionersplayacrucialroleastheprimarycareprovidersforinitiatingoroptimizing lipid-reducingtherapy,whereascardiologistsareinvolvedinmanagingmorecomplexcasesrequiring specializedintervention.TheprimaryobjectiveoftheENNAProjectistoincreasethepercentageofpatients atgreatriskinwhomLDL-Ctargetsareachieved,improvingoveralllipidmanagementandthera-peutic adherence.